| Transplante celular para lesiones medulares con atención en las células madre pluripotenciales inducidas |
Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells.
Nakamura M, Okano H.
Department of Orthopedics, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku, Tokyo 1608582, Japan.
Cell Res. 2013 Jan;23(1):70-80. doi: 10.1038/cr.2012.171. Epub 2012 Dec 11.
Abstract
Stimulated by the 2012 Nobel Prize in Physiology or Medicine awarded for Shinya Yamanaka and Sir John Gurdon, there is an increasing interest in the induced pluripotent stem (iPS) cells and reprograming technologies in medical science. While iPS cells are expected to open a new era providing enormous opportunities in biomedical sciences in terms of cell therapies and regenerative medicine, safety-related concerns for iPS cell-based cell therapy should be resolved prior to the clinical application of iPS cells. In this review, the pre-clinical investigations of cell therapy for spinal cord injury (SCI) using neural stem/progenitor cells derived from iPS cells, and their safety issues in vivo, are outlined. We also wish to discuss the strategy for the first human trails of iPS cell-based cell therapy for SCI patients.
|
| Avances recientes en células madre y terapia génica para alteraciones neurológicas en epilepsia intratable |
Recent advancements in stem cell and gene therapies for neurological disorders and intractable epilepsy.
Naegele JR, Maisano X, Yang J, Royston S, Ribeiro E.
Department of Biology and Program in Neuroscience and Behavior, Hall Atwater Laboratory, 52 Lawn Avenue, Wesleyan University, Middletown, CT 06459, USA. jnaegele@wesleyan.edu
Neuropharmacology. 2010 May;58(6):855-64
. doi: 10.1016/j.neuropharm.2010.01.019. Epub 2010 Feb 8.
Abstract
The potential applications of stem cell therapies for treating neurological disorders are enormous. Many laboratories are focusing on stem cell treatments for CNS diseases, including spinal cord injury, Amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, multiple sclerosis, stroke, traumatic brain injury, and epilepsy. Among the many stem cell types under testing for neurological treatments, the most common are fetal and adult brain stem cells, embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells. An expanding toolbox of molecular probes is now available to allow analyses of neural stem cell fates prior to and after transplantation. Concomitantly, protocols are being developed to direct the fates of stem cell-derived neural progenitors, and also to screen stem cells for tumorigenicity and aneuploidy. The rapid progress in the field suggests that novel stem cell and gene therapies for neurological disorders are in the pipeline.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838966/pdf/nihms179042.pdf
|
|
No hay comentarios:
Publicar un comentario